.svg){kind=small}
Aug-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Where to Buy
1906 is stocked at 693 licensed dispensaries across New York, Oklahoma, and 5 other states, 203 of them in New York, with the deepest coverage in New York, Brooklyn, Queens, Syracuse, and Schenectady. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
Capsules carried 97.13% share in August 2026 with sales down 45.56% year over year and 2.60% month over month, while Edible slipped to 2.83% share with a 79.86% YoY decline and a 36.80% MoM drop; together these moves pushed total brand sales down 48.05% YoY as the average price fell 6.14% versus last year. Minor lines moved in the opposite direction: Pre-Roll expanded 56.09% YoY and 54.32% MoM, and Concentrates rose 23.61% YoY despite holding just 0.02% and 0.02% share respectively, indicating growth at the fringes cannot offset a Capsules-led contraction. The pattern implies a concentration risk where a small MoM dip in Capsules (-2.60%) disproportionately drives overall decline, suggesting that mix diversification is necessary to buffer the brand’s exposure to large YoY swings in its core.
With Capsules at 97.13% share and ranked 1 in Capsules in Illinois, the brand’s leadership position depends on stabilizing that category’s trajectory despite a 45.56% YoY decline, because even double‑digit gains in Pre-Roll (54.32% MoM) and Concentrates (23.61% YoY) barely move total share. The steep Edible contraction (-79.86% YoY and -36.80% MoM) at a higher average price point ($25.84) versus Capsules ($19.56) reduces up‑tier pricing opportunities as overall average price slid 6.14% YoY, implying margin headwinds alongside volume risk. The implication is a positioning shift toward a value‑anchored Capsules core with limited premium mix, where defending rank in Capsules while selectively scaling the fastest‑growing adjacencies is required to mitigate volatility from single‑category dependence.
Competitive Landscape
1906 sits at rank #1 in NY Capsules in August 2026, unchanged from #1 a year earlier, while also holding #1 for the past three months; in contrast, Level holds #2 with a year-over-year decline of 4.4% and Canna Clinicals improved its position from #5 to #4 alongside a 170.0% year-over-year sales change. Meanwhile, Revival slipped from #4 to #5 despite 62.2% year-over-year sales growth, and Grassroots holds #3 with no reported year-over-year rank; the mix of a flat #1 for 1906 and upward pressure from lower ranks implies a stable lead that depends on defending share as faster-moving challengers compress the gap.
Notable Products
CBD/THC 1:1 Go Tablets 20-Pack (100mg CBD, 100mg THC) posted the steepest decline in August 2026 at -15.2% while dropping to rank 5, contrasting with CBD/THC 1:1 Bliss Tablets 20-Pack (100mg CBD, 100mg THC) up 7.3% at rank 1; this divergence indicates shifting mix within the Capsules lineup rather than a category-wide pullback. CBD/THC 1:1 Genius Drops 30-Pack (75mg CBD, 75mg THC) fell -21.7% at rank 7 as CBD/THC 1:1 Love Drops 30-Pack (75mg CBD, 75mg THC) decreased -21.7% at rank 8, while CBD/THC/CBN 2:2:1 Sleep for ZZZ'S Drops 20-Pack (100mg CBD, 100mg THC, 40mg CBN) grew 5.8% at rank 4; with ten of the top ten coming from Capsules, the concentration points to format dominance but with clear preference for tablet-led SKUs over drops. The leader CBD/THC 1:1 Bliss Tablets 20-Pack (100mg CBD, 100mg THC) generated $223,937 alongside a 9.8% lift for CBD/THC 1:1 Bliss Drops Pouch 2-Pack (10mg CBD, 10mg THC) at rank 9, while Boost Drops Pills 20-Pack (100mg) slipped -4.3% at rank 2; the pattern implies 1906’s commercial direction is consolidating around a hero tablet SKU with selective support for sleep and micro-pack line extensions.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
